Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders.
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma.Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 17, 2003 | Series B | $30M | 1 | Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | Yes | Series B |